Ranibizumab biosimilar is under clinical development by Coherus BioSciences and currently in Pre-Registration for Diabetic Macular Edema. According to GlobalData, Pre-Registration drugs for Diabetic Macular Edema have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how Ranibizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Smarter leaders trust GlobalData
Ranibizumab biosimilar overview
Ranibizumab biosimilar (CHS-3351) is under development for the treatment of wet age-related macular degeneration, macular edema secondary to retinal vein occlusion (CRVO and BRVO), diabetic macular edema and diabetic retinopathy. The drug candidate is administered through the intravitreal route. It is a monoclonal antibody fragment (Fab) created from mouse antibody and produced through microbial culture that acts by targeting VEGF-A.
Coherus BioSciences overview
Coherus BioSciences (Coherus) is a biosimilar platform company that develops and commercializes biosimilar drugs. The company’s pipeline product candidates include CHS-1701, an pegfilgrastim used to treat febrile neutropenia; CHS-0214, is an etanercept biosimilar candidate which is used for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis, psoriasis, psoriasis arthritis and rheumatoid arthritis; and CHS-1420, is a adalimumab biosimilar candidate, which is being developed to treat crohn’s disease, ulcerative colitis, and psoriasis arthritis, UDENYCA is a pegfilgrastim biosimilar, CHS-3351 a ranibizumab biosimilar, CHS-2020 a aflibercept biosimilar and CHS-131 a Selective PPAR-gamma modulator. Coherus capabilities includes process science, analytical characterization, protein production and clinical-regulatory development. The company develops drugs in collaboration with other organizations. Coherus is headquartered in Redwood City, California, the US.
For a complete picture of Ranibizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
